CanProX

A Diagnostic Test to Indicate Breast Cancer Patients for Radiotherapy Treatment.

 Background  

Approximately 70% of breast cancer patients receive radiotherapy as part of their curative treatment. However, the outcomes can vary significantly as not all patients respond to this treatment. Luminal A type breast cancer, the most common subtype, requires better stratification methods to personalize radiotherapy treatment to identify patients who are expected to respond to RT. The CanProX test addresses this gap by identifying patients who will benefit most from radiotherapy, reducing unnecessary treatments and improving patient outcomes. 

Business Opportunity 

We are seeking R&D collaboration with industrial partners or potential licensees to bring the CanProX test to market. CanProX diagnostic test represents a significant advancement in personalized medicine, addressing a critical unmet need in implementation of breast cancer radiotherapy. With approximately 1.2 million cases of Luminal A breast cancer annually, this diagnostic tool offers a targeted solution for optimizing treatment outcomes. By incorporating CanProX, companies can leverage its innovative approach to enhance their product portfolios, contribute to precision oncology, and capitalize on a large and growing market in breast cancer diagnostics. 

Technology  

CanProX is a molecular test based on a 33-protein hypoxia signature (33P) that stratifies Luminal A breast cancer patients for radiotherapy. By analyzing the expression of these proteins, the test can predict the likelihood of radiotherapy success in Luminal A breast cancer patients. This data-driven solution offers a competitive edge over existing, less targeted approaches, ensuring more precise treatment plans.  

Project Status  

Currently at a Technology Readiness Level (TRL) of 4, CanProX is progressing through validation and optimization phases. The patent application is pending in the US. 

Contact Information  

For more information or to discuss partnership or licensing opportunities, please contact:  

Malgorzata Barczyk

Senior forretningsutvikler

mba@visinnovasjon.no  

 +47 480 82 052  

CanProX diagnostic test offers a cutting-edge solution to an unmet need in breast cancer treatment. Its ability to personalize radiotherapy treatment plans will not only improve patient outcomes but also align with healthcare cost-saving initiatives. With a large target market and a clear pathway for commercialization, CanProX is set to become a key player in the breast cancer diagnostics landscape.